Table 4. Serum levels of oxidative stress and antioxidant system indicators.
Measures | Weeks | Placebo (n = 30) | PG 1 g (n = 29) | PG 2 g (n = 29) | P-value | Multiple Comparison |
Week 0 | 187.1±24.0 | 187.0±22.1 | 188.9±17.1 | Plac. vs. PG1: 0.035 | ||
ROS (unit/mL) | Week 4 | 164.0±16.5 | 151.0±16.0 | 146.8±26.9 | 0.031 | Plac. vs. PG2: 0.031 |
95% CI* | 11.9∼33.8 | 28.0∼42.1 | 31.0∼53.1 | PG1. vs. PG2: 0.939 | ||
Week 0 | 17.5±5.3 | 18.7±4.5 | 18.4±6.3 | Plac. vs. PG1: 0.028 | ||
MDA (µM) | Week 4 | 16.7±5.7 | 14.3±4.1 | 13.4±3.7 | 0.009 | Plac. vs. PG2: 0.009 |
95% CI | −2.2∼3.5 | 2.6∼6.1 | 2.8∼7.3 | PG1. vs. PG2: 0.665 | ||
Week 0 | 223.7±47.9 | 237.3±31.4 | 220.1±31.9 | |||
TAC (µM) | Week 4 | 239.6±64.9 | 274.1±88.5 | 277.0±150.0 | 0.147 | Not done |
95% CI | −44.0∼17.1 | −68.8∼−4.9 | −113.8∼−5.7 | |||
Week 0 | 1.60±0.70 | 1.03±0.56 | 1.76±0.52 | |||
SOD (unit/mL) | Week 4 | 1.25±0.60 | 0.88±0.34 | 1.45±0.60 | 0.784 | Not done |
95% CI | 0.08∼0.65 | −0.06∼0.35 | 0.08∼0.54 | |||
Week 0 | 606.9±167.9 | 649.6±196.2 | 572.5±108.4 | |||
Catalase (unit/mL) | Week 4 | 659.6±127.3 | 702.8±228.3 | 601.3±81.9 | 0.645 | Not done |
95% CI | −122.3∼12.5 | −144.5∼37.9 | −70.5∼13.0 | |||
Week 0 | 56.5±9.9 | 57.4±5.8 | 60.8±7.9 | Plac. vs. PG1: 0.043 | ||
GSH contents (µM) | Week 4 | 55.4±7.2 | 61.1±7.4 | 61.2±5.1 | 0.043 | Plac. vs. PG2: 0.508 |
95% CI | −2.5∼5.7 | −6.0∼−1.3 | −3.8∼2.8 | PG1. vs. PG2: 0.170 | ||
Week 0 | 0.10±0.04 | 0.08±0.04 | 0.09±0.03 | |||
GSH-Px (unit/mL) | Week 4 | 0.14±0.04 | 0.11±0.04 | 0.12±0.09 | 0.833 | Not done |
95% CI | −0.07∼−0.01 | −0.05∼−0.01 | −0.07∼0.00 | |||
Week 0 | 0.44±0.06 | 0.37±0.06 | 0.43±0.04 | Plac. vs. PG1: 0.021 | ||
GSH-Rd (unit/mL) | Week 4 | 0.41±0.16 | 0.42±0.05 | 0.43±0.07 | 0.021 | Plac. vs. PG2: 0.595 |
95% CI | −0.04∼0.08 | −0.07∼−0.02 | −0.02∼0.03 | PG1. vs. PG2: 0.072 |
Data were expressed as mean ± standard deviation (SD).
95% confidence interval (CI) came from the changed values between week 0 and week 4.